My Cart

Human TL1A / TNFSF15 Protein, His Tag (Monomer) (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
TLA-H5246-100ug
$415.00
TLA-H5246-1mg
$2855.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Synonyms

    TL1A, VEGI, TNFSF15

  • Source

    Human TL1A Protein, His Tag (TLA-H5246) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    TL1A Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 22.4 kDa. The protein migrates as 26 kDa and 28-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    TL1A SDS-PAGE

    Human TL1A Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    TL1A SEC-MALS

    The purity of Human TL1A Protein, His Tag (Cat. No. TLA-H5246) is more than 90% and the molecular weight of this protein is around 25-40 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     TL1A ELISA

    Immobilized Human DcR3, Fc Tag (Cat. No. TNB-H5255) at 5 μg/mL (100 μL/well) can bind Human TL1A Protein, His Tag (Cat. No. TLA-H5246) with a linear range of 8-125 ng/mL (QC tested).

    Protocol
  •  TL1A ELISA

    Human TL1A Protein, His Tag (Cat. No. TLA-H5246) induced NF-κB Reporter activity in Jurkat Cell. The EC50 value of this effect is 1.163 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     TL1A SPR

    Anti-TL1A antibody captured on Protein A Chip can bind Human TL1A Protein, His Tag (Cat. No. TLA-H5246) with an affinity constant of 0.293 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  TL1A SPR

    Human DcR3, Fc Tag (Cat. No. TNB-H5255) captured on Protein A Chip can bind Human TL1A Protein, His Tag (Cat. No. TLA-H5246) with an affinity constant of 0.497 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor superfamily member 15

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    18 Details

  • Highest Development Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background